Research programme: oncolytic Coxsackievirus variants - Viralytics

Drug Profile

Research programme: oncolytic Coxsackievirus variants - Viralytics

Alternative Names: CVA13 DAFv; CVA15 DAFv; CVA18 DAFv; CVA21 DAFv

Latest Information Update: 16 Aug 2013

Price : $50

At a glance

  • Originator ViroTarg
  • Developer University of Newcastle, Australia; Viralytics
  • Class Oncolytic viruses
  • Mechanism of Action CD55 antigen inhibitors; Cell death stimulants; Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Aug 2013 Preclinical development is ongoing in Australia
  • 12 May 2008 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top